-
Gemphire Therapeutics Could Have A Blockbuster Drug In Development
Tuesday, September 6, 2016 - 11:38am | 378Read More...Laidlaw’s Jim Molloy believes Gemphire Therapeutics Inc’s (NASDAQ: GEMP) lead product candidate, Gemcabene, has the potential to become one of the most interesting entrants to the cardiovascular disease (CVD) space, with “true blockbuster potential.” Molloy initiated...
-
UPDATE: Janney Capital Markets Initiates Coverage on Impax Laboratories as The Last Mid-Cap Generics Company Standing
Wednesday, November 13, 2013 - 9:38am | 193Read More...In a report published Wednesday, Janney Capital Markets analyst Jim Molloy initiated coverage on Impax Laboratories (NASDAQ: IPXL) with a Buy rating and $30.00 price target. In the report, Janney Capital Markets noted, “We are initiating coverage of Impax Laboratories (IPXL) with a BUY rating and...
-
UPDATE: Janney Capital Markets Initiates Coverage on Durata Therapeutics on Fundamentally Changing Antibiotic Treatment
Wednesday, November 13, 2013 - 9:38am | 163Read More...In a report published Wednesday, Janney Capital Markets analyst Jim Molloy initiated coverage on Durata Therapeutics (NASDAQ: DRTX) with a Buy rating and $19.00 price target. In the report, Janney Capital Markets noted, “We are initiating coverage of Durata Therapeutics (DRTX) with a Buy rating...
-
UPDATE: Janney Capital Markets Initiates Coverage on Flamel Technologies SA on Transition to Positive Earnings & Cash Flow
Wednesday, November 13, 2013 - 9:36am | 198Read More...In a report published Wednesday, Janney Capital Markets analyst Jim Molloy initiated coverage on Flamel Technologies SA (NASDAQ: FLML) with a Buy rating and $11.00 price target. In the report, Janney Capital Markets noted, “We are initiating coverage on Flamel Technologies (FLML) with a Buy rating...
